

## Director/PDMR Shareholding

### Transactions by Person Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

On 1 September 2014, Luke Miels, EVP, Global Product and Portfolio Strategy, a person discharging managerial responsibilities, was granted awards under the terms of the AstraZeneca Investment Plan (AZIP), the AstraZeneca Performance Share Plan (AZPSP) and the AstraZeneca Restricted Share Plan (AZRSP) over the Company's Ordinary Shares of US\$0.25 each. A summary of these plans and information about the performance measures that relate to the AZIP and AZPSP awards is set out in the Directors' Remuneration Report in the AstraZeneca Annual Report and Form 20-F Information 2013 which is available on the Company's website [www.astrazeneca.com](http://www.astrazeneca.com).

Name	Shares	Shares	Shares	Award price per share
	awarded under AZIP	awarded under AZPSP	awarded under AZRSP	
Luke Miels	4,306	25,839	23,328	4499p

The AZIP award is subject to a four-year performance period (1 January 2014 to 31 December 2017) and a subsequent four-year holding period (1 January 2018 to 31 December 2021).

The AZPSP award is subject to a three-year performance period (1 January 2014 to 31 December 2016).

The AZRSP award will vest, subject to Mr Miels' continued employment with the Company, as follows:

7,776 shares will vest on 7 May 2015

7,776 shares will vest on 7 May 2016

7,776 shares will vest on 7 May 2017

Mr Miels commenced employment with the Company on 7 May 2014. All of the awards, which were approved by the Remuneration Committee, result from a combination of the normal operation of the Company's long-term incentive plans for 2014 and arrangements to compensate Mr Miels for the forfeiture of unvested long-term incentive awards from his previous employer.

A C N Kemp

Company Secretary

10 September 2014